Emcure Pharma forms subsidiary to strengthen dermatology portfolio
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated